Press releases

• Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

  16/09/2021
  DOWNLOAD

• Boehringer Ingelheim and OSE Immunotherapeutics To Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

  13/09/2021
  DOWNLOAD

• OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

  07/09/2021
  DOWNLOAD

• OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13 – 15, 2021 (Virtual Conference)

  01/09/2021
  DOWNLOAD

• OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

  26/08/2021
  DOWNLOAD

• Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

  25/08/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day

  24/08/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

  19/07/2021
  DOWNLOAD

• OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank

  09/07/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine

  30/06/2021
  DOWNLOAD

• OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting

  24/06/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting – Live Webcast Login Information

  03/06/2021
  DOWNLOAD

• OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer

  27/05/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

  26/05/2021
  DOWNLOAD

• OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021

  20/05/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

  18/05/2021
  DOWNLOAD

• OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market

  26/04/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation

  06/04/2021
  DOWNLOAD

• OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

  01/04/2021
  DOWNLOAD

• OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update

  26/03/2021
  DOWNLOAD

• OSE Immunotherapeutics and ARCAGY – GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

  15/03/2021
  DOWNLOAD

• OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting

  11/03/2021
  DOWNLOAD

• OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference (March 9 – 10, 2021)

  23/02/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011

  17/02/2021
  DOWNLOAD

• OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

  15/02/2021
  DOWNLOAD

• OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

  28/01/2021
  DOWNLOAD

• OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

  25/01/2021
  DOWNLOAD

• OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference

  05/01/2021
  DOWNLOAD

• OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011

  21/12/2020
  DOWNLOAD

• OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine

  18/12/2020
  DOWNLOAD

• OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation

  03/12/2020
  DOWNLOAD

• Presse release November 18, 2020

  18/11/2020

• Press release November 16, 2020

  16/11/2020

• OSE Immunotherapeutics to Present at SITC Annual Meeting And at Additional International Immuno-Oncology Summits

  09/11/2020
  DOWNLOAD

• OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate

  05/11/2020
  DOWNLOAD

• OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation

  30/10/2020
  DOWNLOAD

• OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation

  22/10/2020
  DOWNLOAD

• OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104

  12/10/2020
  DOWNLOAD

• OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020

  21/09/2020
  DOWNLOAD

• OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update

  17/09/2020
  DOWNLOAD

• OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference September, 14 – 16, 2020 (Virtual Conference)

  08/09/2020
  DOWNLOAD

• OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT

  17/08/2020
  DOWNLOAD

• OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’ in Non-Small Cell Lung Cancer at the ESMO Virtual Congress 2020

  28/07/2020
  DOWNLOAD

• OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program

  16/07/2020
  DOWNLOAD

• OSE Immunotherapeutics Announces Results of 2020 Virtual Combined General Meeting

  16/06/2020
  DOWNLOAD

• OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy

  10/06/2020
  DOWNLOAD

• OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology

  09/06/2020
  DOWNLOAD

• OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting – Live Webcast Login Information

  27/05/2020
  DOWNLOAD

• OSE Immunotherapeutics Signs €7 Million Non-Dilutive Loan Agreement Guaranteed by the French State

  26/05/2020
  DOWNLOAD

• OSE Immunotherapeutics Presents CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy – Oral Presentation at AACR Virtual Meeting II 2020

  18/05/2020
  DOWNLOAD

• OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program

  05/05/2020
  DOWNLOAD

• Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer

  01/04/2020
  DOWNLOAD

• OSE Immunotherapeutics Reports 2019 Financial Results and Provides Business Update – Expectations for Potential Impact of COVID-19 on the Company’s Clinical Development Activities

  26/03/2020
  DOWNLOAD

• OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases

  17/03/2020
  DOWNLOAD

• OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico

  12/02/2020
  DOWNLOAD

• OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi® on Inducing Early T-Lymphocyte Memory Response

  14/01/2020
  DOWNLOAD

• OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127

  02/12/2019
  DOWNLOAD

• OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

  27/11/2019
  DOWNLOAD

• OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi® At the 34th SITC Annual Meeting

  11/11/2019
  DOWNLOAD

• OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation

  07/11/2019
  DOWNLOAD

• OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines To Overcome Tumor Resistance to Checkpoint Inhibitor Blockade

  30/09/2019
  DOWNLOAD

• OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063

  18/09/2019
  DOWNLOAD

• OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update

  05/09/2019
  DOWNLOAD

• OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients

  03/09/2019
  DOWNLOAD

• OSE Immunotherapeutics Receives a Grant from the French National Research Agency to Validate New Targets Linked to Myeloid Cells and Identify Innovative New Immunotherapies in Oncology

  23/07/2019
  DOWNLOAD

• First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation

  17/07/2019
  DOWNLOAD

• OSE Immunotherapeutics Receives Special Recognition for European Growth, Healthcare Enterprise and Women Entrepreneurship Awarded by Forbes, PME Finance – Europe Entrepreneurs and their Partners

  10/07/2019
  DOWNLOAD

• OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

  26/06/2019
  DOWNLOAD

• OSE Immunotherapeutics will participate in HealthTech Investor Days (HTID), Event hosted by France Biotech on 24th & 25th June in Paris

  24/06/2019
  DOWNLOAD

• Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation

  20/06/2019
  DOWNLOAD

• Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

  17/06/2019
  DOWNLOAD

• OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis

  11/06/2019
  DOWNLOAD

• OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum to be held in Chicago, IL, on May 31, 2019

  28/05/2019
  DOWNLOAD

• OSE Immunotherapeutics to Host Key Opinion Leader Meeting on Novel Treatments in Non-Small Cell Lung Cancer – Meeting Scheduled for May 30, 2019 in New York City

  22/05/2019
  DOWNLOAD

• OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127

  20/05/2019
  DOWNLOAD

• OSE Immunotherapeutics Announces Publication on Anti-IL-7 Receptor Antagonist, OSE-127, in The Journal of Clinical Investigation

  11/04/2019
  DOWNLOAD

• OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104

  09/04/2019
  DOWNLOAD

• OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019

  02/04/2019
  DOWNLOAD

• OSE Immunotherapeutics Reports 2018 Financial Results and Business Update

  28/03/2019
  DOWNLOAD

• OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies to Identify Novel Immuno-Oncology Targets

  26/03/2019
  DOWNLOAD

• OSE Immunotherapeutics Presents its Novel Bispecific Checkpoint Inhibitor Platform, Targeting PD-1 and Innovative Targets

  07/03/2019
  DOWNLOAD

• OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate Selective SIRPα antagonist BI 765063 under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors

  05/03/2019
  DOWNLOAD

• OSE Immunotherapeutics to Present New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019, Oral presentation will highlight early signs of activity of Tedopi® from the ongoing Phase 3 trial in NSCLC

  28/02/2019
  DOWNLOAD

• OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases

  07/02/2019
  DOWNLOAD

• OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis

  15/01/2019
  DOWNLOAD

• OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference During JP Morgan Healthcare Conference San Francisco, January 7-9, 2019

  03/01/2019
  DOWNLOAD

• OSE Immunotherapeutics Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of OSE-127

  20/12/2018
  DOWNLOAD

• OSE Immunotherapeutics Appoints Julien Perrier Chief Commercial Officer

  17/12/2018
  DOWNLOAD

• OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage Anti-Interleukin-7 Receptor Antagonist OSE-127 at Two International Scientific Conferences

  10/12/2018
  DOWNLOAD

• OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127

  26/11/2018
  DOWNLOAD

• OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer

  20/11/2018
  DOWNLOAD

• OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech

  02/11/2018
  DOWNLOAD

• OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)

  29/10/2018
  DOWNLOAD

• OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of a Clinical Trial Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer

  10/10/2018
  DOWNLOAD

• OSE Immunotherapeutics to Present at the 18th Annual Biotech in Europe Investor Forum, Oct. 4-5, 2018, Congress Center Basel

  01/10/2018
  DOWNLOAD

• OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update

  06/09/2018
  DOWNLOAD

• OSE Immunotherapeutics Publishes New Efficacy Data on FR104, CD28-Antagonist Immunotherapy

  22/08/2018
  DOWNLOAD

• OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy

  22/08/2018
  DOWNLOAD

• OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi®

  05/07/2018
  DOWNLOAD

• OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

  02/07/2018
  DOWNLOAD

• OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting

  13/06/2018
  DOWNLOAD

• OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum Forum to be held in Chicago, IL, on June 1, 2018

  17/05/2018
  DOWNLOAD

• OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting

  07/05/2018
  DOWNLOAD

• OSE Immunotherapeutics Receives the Euronext Tech40 Label

  23/04/2018
  DOWNLOAD

• OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management

  12/04/2018
  DOWNLOAD

• OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership

  05/04/2018
  DOWNLOAD

• Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

  04/04/2018
  DOWNLOAD

• OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products – Key Clinical Portfolio Development Progress Planned for 2018

  28/03/2018
  DOWNLOAD

• OSE Immunotherapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

  27/03/2018
  DOWNLOAD

• OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, Chicago, April 14-18

  19/03/2018
  DOWNLOAD

• OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment – Phase 3 Trial received Approval to be Initiated in Israel

  15/03/2018
  DOWNLOAD

• OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®, Amsterdam, March 12-14, 2018

  28/02/2018
  DOWNLOAD

• OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

  27/02/2018
  DOWNLOAD

• OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Applications

  25/01/2018
  DOWNLOAD

• OSE Immunotherapeutics to present at Biotech Showcase™ 2018 Conference

  04/01/2018
  DOWNLOAD

• OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors

  03/01/2018
  DOWNLOAD

• OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases

  19/12/2017
  DOWNLOAD

• OSE Immunotherapeutics Receives a Grant from French Government Program “Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies – Company’s Monoclonal Antibody, OSE-703, to be Significant Focus of Research

  14/12/2017
  DOWNLOAD

• OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

  07/12/2017
  DOWNLOAD

• OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

  19/10/2017
  DOWNLOAD

• OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment

  02/10/2017
  DOWNLOAD

• OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells

  28/09/2017
  DOWNLOAD

• Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

  26/09/2017
  DOWNLOAD

• OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio

  07/09/2017
  DOWNLOAD

• OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer

  06/09/2017
  DOWNLOAD

• OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference, In New York City, September 10-12, 2017

  31/08/2017
  DOWNLOAD

• OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)

  19/07/2017
  DOWNLOAD

• OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer

  23/06/2017
  DOWNLOAD

• OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127

  21/06/2017
  DOWNLOAD

• OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases

  15/06/2017
  DOWNLOAD

• OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders

  14/06/2017
  DOWNLOAD

• OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York Focused on Company’s Cytotoxic Monoclonal Antibody OSE-703 targeting IL-7R to treat cancer

  12/06/2017
  DOWNLOAD

• Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

  23/05/2017
  DOWNLOAD

• OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists

  22/05/2017
  DOWNLOAD

• OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum

  18/05/2017
  DOWNLOAD

• OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress”, London, May 15-16, 2017

  15/05/2017
  DOWNLOAD

• OSE Immunotherapeutics Presented New Data at AACR Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Anti-tumoral Potent T Memory Response

  05/04/2017
  DOWNLOAD

• 2016 Results: Significant Milestones, First Profit, More Growth to Come

  28/03/2017
  DOWNLOAD

• OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24th Molecular Med TRI-CON 2017 Meeting

  21/02/2017
  DOWNLOAD

• OSE Immunotherapeutics Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

  24/01/2017
  DOWNLOAD

• OSE Immunotherapeutics to present at Biotech Showcase™ 2017 Conference

  04/01/2017
  DOWNLOAD

• OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7

  28/12/2016
  DOWNLOAD

• OSE Immunotherapeutics appoints Dr. Frédérique Corallo, as Chief Medical Officer, Immunology

  28/11/2016
  DOWNLOAD

• OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology

  28/11/2016
  DOWNLOAD

• Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases

  15/11/2016
  DOWNLOAD

• OSE Immunotherapeutics Awarded First Prize and “Listed Company” Prize as part of 2016 Deloitte In Extenso Technology Fast 50 Ouest

  15/11/2016
  DOWNLOAD

• OSE Immunotherapeutics to present at 2016 MedStart Up Days, New York City, October 27th & 28th, 2016

  24/10/2016
  DOWNLOAD

• OSE Immunotherapeutics to present the preclinical data of its new checkpoint inhibitor Effi-DEM on SIRP-α/CD47 strategic pathway at the 2016 Immune Checkpoint Inhibitors Conference

  04/10/2016
  DOWNLOAD

• OSE Immunotherapeutics to present Atalante 1, the registration clinical trial of Tedopi®, ongoing in the U.S. and in Europe,

  20/09/2016
  DOWNLOAD

• OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director

  15/09/2016
  DOWNLOAD

• OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results Driven by Key Clinical Milestones

  08/09/2016
  DOWNLOAD

• OSE Immunotherapeutics will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City, September 11-13, 2016

  30/08/2016
  DOWNLOAD

• OSE Immunotherapeutics presents new preclinical efficacy results with Effi-DEM, a new generation checkpoint inhibitor, at the “European Association for Cancer Research” (EACR) Congress – (Manchester, 9-12 July 2016)

  12/07/2016
  DOWNLOAD

• OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation in autoimmune diseases

  05/07/2016
  DOWNLOAD

• OSE Immunotherapeutics presents significant preclinical efficacy results for Effi-7, an antagonist of the IL-7 receptor

  27/06/2016
  DOWNLOAD

• OSE Immunotherapeutics presents significant preclinical results for new generation checkpoint inhibitor, Effi-DEM

  20/06/2016
  DOWNLOAD

• Publication of the 2015 Reference Document

  09/06/2016
  DOWNLOAD

• OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics

  31/05/2016
  DOWNLOAD

• Launch of a non-interventional study in hepatocellular carcinoma

  19/05/2016
  DOWNLOAD

• Dominique Costantini, Co-Founder of OSE Pharma, invited to “Bpifrance Inno Génération”

  18/05/2016
  DOWNLOAD

• Presentation of the future entity OSE Immunotherapeutics at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum »

  12/05/2016
  DOWNLOAD

• Effimune and OSE Pharma announce the online publication of Preclinical efficacy data for FR104 in a renal allograft model in the « Journal of the American Society of Nephrology »

  11/05/2016
  DOWNLOAD

• Availability of preparatory documents for the combined General Meeting of May 31, 2016

  27/04/2016
  DOWNLOAD

• OSE Pharma and Effimune announce the signing of the Merger Treaty to create OSE Immunotherapeutics

  15/04/2016
  DOWNLOAD

• Fifth country opens recruitment in the global pivotal Phase 3 trial of the immunotherapy Tedopi with initiation in Hungary

  11/04/2016
  DOWNLOAD

• OSE Pharma to join workshop “Phase I: An inflection point in drug development and value generation” at BIO Europe Spring 2016

  04/04/2016
  DOWNLOAD

• OSE Pharma to attend the Small & Midcap Event in Paris on 11 & 12 April, 2016

  29/03/2016
  DOWNLOAD

• 2015: Annual Results in line with forecasts and significant advances – 2016 outlook : further development and merger project with Effimune

  21/03/2016
  DOWNLOAD

• First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi® for advanced Non-Small Cell Lung Cancer

  22/02/2016
  DOWNLOAD

• OSE Pharma announces U.S. initiation of Atalante 1, the Company’s global, pivoltal Phase 3 trial for Tedopi® immunotherapy in Non-Small Cell Lung Cancer

  04/02/2016
  DOWNLOAD

• OSE Pharma anounces initiation of its pivotal Phase 3 trial of Tedopi® in Non-Small Cell Lung Cancer

  06/01/2016
  DOWNLOAD

• OSE Pharma announces its events for Q1 2016

  05/01/2016
  DOWNLOAD

• OSE Pharma announces selection of 70 international clinical centers to participate in its pivotal Phase 3 trial of Tedopi® for patients diagnosed with advanced non-small cell lung cancer (NSCLC)

  23/12/2015
  DOWNLOAD

• OSE Pharma to participate to Biotech Showcase™ during JP Morgan Healthcare Conference San Francisco – January 11-13, 2016

  14/12/2015
  DOWNLOAD

• OSE Pharma admitted to Long-Only Deferred Settlement Service

  07/12/2015
  DOWNLOAD

• OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi®

  02/11/2015
  DOWNLOAD

• OSE Pharma successfully completes the manufacturing of the clinical batches for its pivotal Phase 3 clinical trial with Tedopi®

  19/10/2015
  DOWNLOAD

• OSE Pharma participe au Large & Midcap Event à Paris les 7 et 8 octobre 2015

  29/09/2015
  DOWNLOAD

• OSE Pharma intègre les indices CAC® Small, CAC® Mid & Small et CAC® All-Tradable

  16/09/2015
  DOWNLOAD

• OSE Pharma sera à BioPharm America les 15 et 16 septembre 2015 à Boston, Etats-Unis

  14/09/2015
  DOWNLOAD

• OSE Pharma dévoile des résultats cliniques et immunologiques de son étude de Phase 2 chez les patients avec métastases cérébrales traités avec Tedopi® lors de la Conférence Mondiale sur le Cancer du Poumon à Denver aux Etats Unis.

  09/09/2015
  DOWNLOAD

• OSE Pharma annonce une première étape dans le lancement de son étude de phase 3 dans le cancer du poumon : Constitution de son comité de pilotage

  01/09/2015
  DOWNLOAD

• Présentation des résultats cliniques de Tedopi pour des patients atteints de métastases cérébrales liées à un cancer du poumon lors de la 16ème Conférence Mondiale sur le Cancer du Poumon

  23/07/2015
  DOWNLOAD

• Résultats du vote de l’Assemblée Générale Mixte du 23 juin 2015

  23/06/2015
  DOWNLOAD

• Mise à disposition du Document de Référence 2014

  18/06/2015
  DOWNLOAD

• OSE Pharma participe aux « French Life Science Days » les 17 et 18 juin 2015 à New York

  15/06/2015
  DOWNLOAD

• OSE Pharma sera présente à BIO International Convention du 15 au 18 juin 2015 à Philadelphie

  08/06/2015
  DOWNLOAD

• Mise à disposition des documents préparatoire à l’AGM du 23 juin 2015

  02/06/2015
  DOWNLOAD

• OSE Pharma signe son premier accord d’exploitation pour Tedopi® avec les laboratoires RAFA

  11/05/2015
  DOWNLOAD

• Mise à disposition du Rapport Financier Annuel 2014

  24/04/2015
  DOWNLOAD

• OSE Pharma acteur de l’équipe de France des biotechnologies médicales

  17/04/2015
  DOWNLOAD

• Très large succès de l’introduction en Bourse d’OSE Pharma 30 mars : 1er jour de cotation

  30/03/2015
  DOWNLOAD

• OSE Pharma lance son introduction en bourse

  09/03/2015
  DOWNLOAD

• Enregistrement du document de base

  17/09/2014
  DOWNLOAD

• Tedopi®, un nouvel espoir dans l’immunothérapie du cancer du poumon

  12/09/2014
  DOWNLOAD

• OSE Pharma lève 3,2 M€

  29/07/2014
  DOWNLOAD

• Protocole d’essai clinique de phase 3 pour Tedopi® accepté par la FDA et l’EMA

  23/06/2014
  DOWNLOAD

• OSE Pharma acquiert les actifs de Texopi®, les droits mondiaux et du savoir-faire (en anglais)

  07/04/2014
  DOWNLOAD

• OSE Pharma renforce son Conseil d’Administration (en anglais)

  12/11/2013
  DOWNLOAD

• Nomination du Professeur Fridman en tant que Président du Comité scientifique (en anglais)

  12/11/2013
  DOWNLOAD

• OSE PHARMA annonce l’obtention d’un financement d’OSEO/BPIFrance pour son immunothérapie du cancer en phase 3 (en anglais)

  04/06/2013
  DOWNLOAD

• Premier brevet européen pour OSE PHARMA (en anglais)

  31/01/2013
  DOWNLOAD

• OSE Pharma to attend BIO-Europe 2015 The conference will take place on November 2-4 in Munich, Germany

  DOWNLOAD

• OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress

  DOWNLOAD

• OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE® (Berlin, 6-8 November 2017)

  DOWNLOAD